Eli Lilly and Regeneron drive weight-loss ETF higher
Alpha Vantage · ETF Database · · AI-summarised by FinFlash
The Amplify Weight Loss Drug & Treatment ETF (THNR) returned 3.2% in October, led by Eli Lilly and Regeneron Pharmaceuticals. Lilly's third-quarter results beat Wall Street expectations on strong Zepbound and Mounjaro sales, while Regeneron posted a 36% revenue jump and reported progress in obesity trials. Analysts hold 26 Buy ratings on the group, signaling continued confidence in weight-loss exposure.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.